Skip to content
Review Open access

Pneumocystis jirovecii Pneumonia in a Kidney Transplant Recipient: A Case Report and Regional Literature Review

Oct 2026 · European Journal of Medical and Health Research · 0 citations · 8 references

Abstract

Background: Pneumocystis jirovecii pneumonia (PJP) is a significant opportunistic infection in kidney transplant recipients, with a prevalence of ~1.28% in late-onset settings and mortality 10–50%. Despite TMP-SMX prophylaxis, PJP occurs with intensified immunosuppression, acute rejection, or CMV co-infection. Its nonspecific presentation delays diagnosis and worsens outcomes. Late-onset PJP is recognized. Case Presentation: A 29-year-old male kidney transplant recipient developed PJP eleven months post-transplantation from his HLA semi-identical mother. He presented with fever (39°C), exertional dyspnea, and oxygen saturation 85% on ambient air. Chest radiography showed bilateral alveolar-interstitial infiltrates; CT revealed diffuse ground-glass opacities with septal reticulations ("crazy-paving"). He received oxygen therapy, sulfamethoxazole (10 mg/kg for 28 days), and cefotaxime (15 days), with progressive improvement and stable graft function. Discussion: PJP occurring eleven months post-transplantation despite appropriate immunosuppression highlights challenges in prophylaxis duration and need for individualized risk stratification. Diagnosis relied on radiological findings; bronchoalveolar lavage with PCR remains the gold standard. The patient responded to TMP-SMX. CMV co-infection (26.9– 46.2% of PJP cases) is associated with increased severity and graft failure and was considered. TMP-SMX prophylaxis remains the cornerstone; optimal duration (3–12 months) is debated. The optimal duration of prophylaxis remains uncertain, with guidelines recommending 3 to 12 months depending on institutional protocols. Conclusion: PJP is frequent and potentially life-threatening in kidney transplant recipients. TMP-SMX prophylaxis should be systematic; early diagnosis and treatment are essential. Clinicians should maintain high suspicion and consider CMV co-infection. Research is needed to identify patients who may benefit from extended prophylaxis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.